BIOMAT Database Logo BIOMAT Database Logo

Alanine Aminotransferase and Gamma-Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis. 2021

Kimberly P Newton, and Joel E Lavine, and Laura Wilson, and Cynthia Behling, and Miriam B Vos, and Jean P Molleston, and Philip Rosenthal, and Tamir Miloh, and Mark H Fishbein, and Ajay K Jain, and Karen F Murray, and Jeffrey B Schwimmer, and
Division of Gastroenterology, Hepatology, and NutritionDepartment of PediatricsUniversity of California San Diego School of MedicineLa JollaCA.

Predictive, noninvasive tools are needed to monitor key features of nonalcoholic fatty liver disease (NAFLD) in children that relate to improvement in liver histology. The purpose of this study was to evaluate the relationship between liver chemistries and liver histology using data from the CyNCh (Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children) clinical trial. This study included 146 children. Improvement in liver histology, defined as decrease in nonalcoholic fatty liver disease (NAFLD) Activity Score ≥2 points without worsening of fibrosis, occurred in 43 participants (30%). There were 46 participants with borderline zone 1 nonalcoholic steatohepatitis (NASH) at baseline, with resolution in 28% (12 of 46). Multivariate models were constructed using baseline and change in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) at 52 weeks, for improvement in (1) liver histology primary outcome, (2) borderline zone 1 NASH, and (3) fibrosis. For improvement in histology, the model (P < 0.0001) retained baseline and change in GGT (area under the receiver operating characteristic [AUROC], 0.79; 95% confidence interval [CI], 0.71-0.87). For borderline zone 1 NASH, the model (P = 0.0004) retained baseline and change in ALT (AUROC, 0.80; 95% CI, 0.67-0.93). For fibrosis, the model (P < 0.001) retained baseline and change in ALT (AUROC, 0.80; 95% CI, 0.67-0.93). Additional clinical parameters were added to the models using Akaike's information criterion selection, and significantly boosted performance: improvement in histology with AUROC of 0.89 (95% CI, 0.82-0.95), borderline zone 1 NASH with AUROC of 0.91 (95% CI, 0.83-0.99), and fibrosis with AUROC of 0.89 (95% CI, 0.82-0.94). Models were validated using data from the TONIC (Treatment of Nonalcoholic Fatty Liver Disease in Children) trial. In children with NAFLD, dynamic changes in serum ALT and GGT are associated with change in liver histology and appear to be powerful indicators of histological response.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003543 Cysteamine A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS. Cysteinamine,Mercaptamine,2-Aminoethanethiol,Becaptan,Cystagon,Cysteamine Bitartrate,Cysteamine Dihydrochloride,Cysteamine Hydrobromide,Cysteamine Hydrochloride,Cysteamine Maleate (1:1),Cysteamine Tartrate,Cysteamine Tartrate (1:1),Cysteamine Tosylate,Cysteamine, 35S-Labeled,Mercamine,Mercaptoethylamine,beta-Mercaptoethylamine,2 Aminoethanethiol,35S-Labeled Cysteamine,Bitartrate, Cysteamine,Cysteamine, 35S Labeled,Dihydrochloride, Cysteamine,Hydrobromide, Cysteamine,Hydrochloride, Cysteamine,Tartrate, Cysteamine,Tosylate, Cysteamine,beta Mercaptoethylamine
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D005260 Female Females
D005723 gamma-Glutamyltransferase An enzyme, sometimes called GGT, with a key role in the synthesis and degradation of GLUTATHIONE; (GSH, a tripeptide that protects cells from many toxins). It catalyzes the transfer of the gamma-glutamyl moiety to an acceptor amino acid. GGTP,Glutamyl Transpeptidase,gammaglutamyltransferase,gamma-Glutamyl Transpeptidase,Transpeptidase, Glutamyl,Transpeptidase, gamma-Glutamyl,gamma Glutamyl Transpeptidase,gamma Glutamyltransferase

Related Publications

Kimberly P Newton, and Joel E Lavine, and Laura Wilson, and Cynthia Behling, and Miriam B Vos, and Jean P Molleston, and Philip Rosenthal, and Tamir Miloh, and Mark H Fishbein, and Ajay K Jain, and Karen F Murray, and Jeffrey B Schwimmer, and
Diagnostic value of gamma-glutamyl transpeptidase to alkaline phosphatase ratio combined with gamma-glutamyl transpeptidase to aspartate aminotransferase ratio and alanine aminotransferase to aspartate aminotransferase ratio in alpha-fetoprotein-negative hepatocellular carcinoma.
July 2021, Cancer medicine,
Kimberly P Newton, and Joel E Lavine, and Laura Wilson, and Cynthia Behling, and Miriam B Vos, and Jean P Molleston, and Philip Rosenthal, and Tamir Miloh, and Mark H Fishbein, and Ajay K Jain, and Karen F Murray, and Jeffrey B Schwimmer, and
Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis.
January 2013, PloS one,
Kimberly P Newton, and Joel E Lavine, and Laura Wilson, and Cynthia Behling, and Miriam B Vos, and Jean P Molleston, and Philip Rosenthal, and Tamir Miloh, and Mark H Fishbein, and Ajay K Jain, and Karen F Murray, and Jeffrey B Schwimmer, and
[Standard values of gamma glutamyl transpeptidase and serum alanine aminotransferase as well as aspartate aminotransferase using substrate-optimized tests].
March 1974, Die Medizinische Welt,
Kimberly P Newton, and Joel E Lavine, and Laura Wilson, and Cynthia Behling, and Miriam B Vos, and Jean P Molleston, and Philip Rosenthal, and Tamir Miloh, and Mark H Fishbein, and Ajay K Jain, and Karen F Murray, and Jeffrey B Schwimmer, and
[Gamma-glutamyl-transpeptidase and gamma-glutamyl-lactamase].
January 1967, Postepy higieny i medycyny doswiadczalnej,
Kimberly P Newton, and Joel E Lavine, and Laura Wilson, and Cynthia Behling, and Miriam B Vos, and Jean P Molleston, and Philip Rosenthal, and Tamir Miloh, and Mark H Fishbein, and Ajay K Jain, and Karen F Murray, and Jeffrey B Schwimmer, and
Gamma-glutamyl-transpeptidase.
January 1990, Annals of the New York Academy of Sciences,
Kimberly P Newton, and Joel E Lavine, and Laura Wilson, and Cynthia Behling, and Miriam B Vos, and Jean P Molleston, and Philip Rosenthal, and Tamir Miloh, and Mark H Fishbein, and Ajay K Jain, and Karen F Murray, and Jeffrey B Schwimmer, and
Gamma-glutamyl transpeptidase.
December 1970, Lancet (London, England),
Kimberly P Newton, and Joel E Lavine, and Laura Wilson, and Cynthia Behling, and Miriam B Vos, and Jean P Molleston, and Philip Rosenthal, and Tamir Miloh, and Mark H Fishbein, and Ajay K Jain, and Karen F Murray, and Jeffrey B Schwimmer, and
[Gamma-glutamyl transpeptidase].
April 1972, Deutsche medizinische Wochenschrift (1946),
Kimberly P Newton, and Joel E Lavine, and Laura Wilson, and Cynthia Behling, and Miriam B Vos, and Jean P Molleston, and Philip Rosenthal, and Tamir Miloh, and Mark H Fishbein, and Ajay K Jain, and Karen F Murray, and Jeffrey B Schwimmer, and
Gamma-glutamyl transpeptidase.
January 1981, Methods in enzymology,
Kimberly P Newton, and Joel E Lavine, and Laura Wilson, and Cynthia Behling, and Miriam B Vos, and Jean P Molleston, and Philip Rosenthal, and Tamir Miloh, and Mark H Fishbein, and Ajay K Jain, and Karen F Murray, and Jeffrey B Schwimmer, and
Gamma-glutamyl transpeptidase.
January 1975, Advances in clinical chemistry,
Kimberly P Newton, and Joel E Lavine, and Laura Wilson, and Cynthia Behling, and Miriam B Vos, and Jean P Molleston, and Philip Rosenthal, and Tamir Miloh, and Mark H Fishbein, and Ajay K Jain, and Karen F Murray, and Jeffrey B Schwimmer, and
[Gamma glutamyl transpeptidase].
August 1973, Deutsche medizinische Wochenschrift (1946),
Copied contents to your clipboard!